Alan Perkins

Author PubWeight™ 7.93^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model.	Cancer Biol Ther	2007	1.85
2	Partial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide.	Proc Natl Acad Sci U S A	2005	1.28
3	Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer.	Bioconjug Chem	2007	0.90
4	Global shortage of medical isotopes threatens nuclear medicine services.	BMJ	2008	0.85
5	Diagnostic imaging.	Lancet	2012	0.80
6	Update: aptamers as novel radiopharmaceuticals: their applications and future prospects in diagnosis and therapy.	Cancer Biother Radiopharm	2007	0.79
7	Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients.	Oncologist	2003	0.76
8	Simple objective measurement of the cutaneous delayed-type hypersensitivity reaction to tuberculin using spectrophotometry.	Skin Res Technol	2002	0.76
9	Interview.	Nucl Med Commun	2014	0.75
10	Comparison of cathode ray tube and liquid crystal display stimulators for use in multifocal VEP.	Doc Ophthalmol	2014	0.75